Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥133.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥27.0bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥26.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥25.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥19.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥285.9bnat 2022-09-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥271.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥128.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥157.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥130.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.3bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥41.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥12.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥9.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥273.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.172022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥342.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.932021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥273.382022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥342.12021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥4.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥746m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥88.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥33m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥4.8bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥12.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-09-30¥14.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥138.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥133.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥4.9bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥27.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 532
ItemContextValueUnit
Increase in cash and cash equivalents from newly consolidated subsidiary ccePrior1YTDDuration0JPY
Increase in cash and cash equivalents from newly consolidated subsidiary cceCurrentYTDDuration－JPY
Cash and cash equivalentsPrior1QuarterInstant41809000000JPY
Cash and cash equivalentsCurrentQuarterInstant37275000000JPY
Salaries and bonuses sgaPrior1YTDDuration5413000000JPY
Salaries and bonuses sgaCurrentYTDDuration5508000000JPY
Provision for bonuses sgaPrior1YTDDuration2602000000JPY
Provision for bonuses sgaCurrentYTDDuration2436000000JPY
Retirement benefit expenses sgaPrior1YTDDuration403000000JPY
Retirement benefit expenses sgaCurrentYTDDuration426000000JPY
Depreciation sgaPrior1YTDDuration1229000000JPY
Depreciation sgaCurrentYTDDuration2340000000JPY
Amortization of goodwill sgaPrior1YTDDuration55000000JPY
Amortization of goodwill sgaCurrentYTDDuration129000000JPY
Commission fee sgaPrior1YTDDuration6378000000JPY
Commission fee sgaCurrentYTDDuration7402000000JPY
Research and development expenses sgaPrior1YTDDuration3334000000JPY
Research and development expenses sgaCurrentYTDDuration3969000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember88801000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember30227000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14710000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember133739000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration133739000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember33000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember4808000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember10000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember4851000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-4851000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember88834000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember35035000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14721000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember138591000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-4851000000JPY
Net salesPrior1YTDDuration133739000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember14727000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember11957000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember1012000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember27697000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-746000000JPY
Operating incomePrior1YTDDuration26951000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember85040000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember35224000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember13817000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember134081000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration134081000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember83000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember4991000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass